Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

Boonen, S; Adachi, J D; Man, Z; Cummings, S R; Lippuner, K; Törring, O; Gallagher, J C; Farrerons, J; Wang, A; Franchimont, N; San Martin, J; Grauer, A; McClung, M (2011). Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. Journal of clinical endocrinology and metabolism, 96(6), pp. 1727-36. Chevy Chase, Md.: Endocrine Society 10.1210/jc.2010-2784

Full text not available from this repository. (Request a copy)

The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis

UniBE Contributor:

Lippuner, Kurt

ISSN:

0021-972X

Publisher:

Endocrine Society

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:21

Last Modified:

17 Mar 2015 19:28

Publisher DOI:

10.1210/jc.2010-2784

PubMed ID:

21411557

Web of Science ID:

000290810200047

URI:

https://boris.unibe.ch/id/eprint/6918 (FactScience: 211990)

Actions (login required)

Edit item Edit item
Provide Feedback